Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Day One Biopharmaceuticals, Inc. - Common Stock
(NQ:
DAWN
)
10.48
-0.26 (-2.42%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Day One Biopharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
May 06, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For May 6, 2025
↗
May 06, 2025
Via
Benzinga
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
April 22, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
February 25, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 25, 2025
↗
February 25, 2025
Via
Benzinga
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
February 11, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Biotech Investing: How PRV’s Can Unlock Major Opportunities (OSTX, DAWN, SWTX, PTCT)
February 05, 2025
Via
AB Newswire
Biotech Investing: How PRVs Can Unlock Major Opportunities
February 05, 2025
Biotech Investing: How PRVs Can Unlock Major Opportunities
Via
News Direct
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities
January 13, 2025
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
November 20, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 18, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
↗
October 31, 2024
Via
Benzinga
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
October 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
October 16, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
↗
August 14, 2024
Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%.
Via
InvestorPlace
Topics
Economy
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
↗
August 01, 2024
Via
Benzinga
DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024
↗
July 30, 2024
DAWN stock results show that Day One Biopharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
July 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Oversubscribed $175.0 Million Private Placement
July 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
↗
July 25, 2024
Via
Benzinga
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
↗
June 22, 2024
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting...
Via
Talk Markets
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
June 18, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Sale of Priority Review Voucher for $108 Million
May 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024
↗
May 06, 2024
DAWN stock results show that Day One Biopharmaceutical missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
May 06, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
April 23, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
February 26, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Two New Appointments to Board of Directors
January 17, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
